

## PUBLICATIONS JONAS BERGH

### PAPERS INCLUDING REVIEWS AND COLLABORATIVE GROUP PUBLICATIONS

1. Bergh J, Nilsson K, Zech L, Giovanella B. Establishment and characterisation of a continuous lung squamous cell carcinoma cell line (U-1752). *Anticancer Research* 1:317-322, 1981.
2. Bergh J, Larsson E, Zech L, Nilsson K. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small cell carcinoma of the lung. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica, Sect A* 90:149-158, 1982.
3. Bergh J, Nilsson K, Cate CC, Pettengill OS, Sorenson GD. Cell surface glycoprotein patterns of cell lines derived from human small cell carcinoma of the lung. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica, Sect A* 91:9-15, 1983.
4. Carlsson J, Nilsson K, Westermark B, Pontén J, Sundström S, Larsson E, Bergh J, Pählman S, Busch C, Collins VP. Formation and growth of multicellular spheroids of human origin. *International Journal of Cancer* 31:523-533, 1983.
5. Nilsson S, Bergh J, Brodin O, Söderström S. Monoklonala antikroppar och tumörassocierade antigener. *Svensk Förening för Medicinsk Radiologi* 17:29-31, 1983.
6. Pählman S, Esscher T, Bergh J, Steinholtz L, Nöu E, Nilsson K. Neuron-specific enolase as a marker for neuroblastoma and small-cell carcinoma of the lung. *Tumour Biology* 5:119-126, 1984.
7. Bergh J, Nilsson K, Dahl D, Andersson L, Virtanen I, Lehto V-P. Expression of intermediate filaments in established human lung cancer cell lines - An indicator of differentiation and derivation. *Laboratory Investigation* 51:307-316, 1984.
8. Bergh J. The biology of human lung cancer in vitro, with special reference to small cell carcinoma. Dr Med Sc Thesis. *Acta Universitatis Upsaliensis*, Nr 506, pp 1-49, 1984.
9. Zech L, Bergh J, Nilsson K. Karyotypic characterization of established cell lines and short-term cultures of human lung cancers. *Cancer Genetics and Cytogenetics* 15:335-347, 1985.
10. Hillerdahl G, Bergh J. Malignant mesothelioma secondary to chronic inflammation and old scars: Two new cases and review of the literature. *Cancer* 55:1968-1972, 1985.
11. Esscher T, Steinholtz L, Bergh J, Nöu E, Nilsson K, Pählman S. Neuronspecific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. *Thorax* 40:85-90, 1985.
12. Bergh J, Esscher T, Steinholtz L, Nilsson K, Pählman S. Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. *American Journal of Clinical Pathology* 84:1-7, 1985.
13. Bergh J, Nilsson K, Ekman R, Giovanella B. Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica, Sect A* 93:133-147, 1985.

14. Saksela K, Bergh J, Lehto V-P, Nilsson K, Alitalo K. Amplification of the *c-myc* oncogene in a subpopulation of human small cell lung cancer. *Cancer Research* 45:1823-1827, 1985.
15. Bergh J, Nilsson K. Surface-glycoprotein patterns of established human lung cancer cell lines and primary cultures *Anticancer Research* 5:323-328, 1985.
16. Gronowitz S, Steinholtz L, Källander C, Hagberg H, Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung: relation to clinical features, prognosis and other biochemical markers. *Cancer* 58:111-118, 1986.
17. Lehto V-P, Bergh J, Virtanen I. Immunohistology in the classification of lung cancer. In: *Lung cancer. Basic and Clinical Aspects*. Ed H Hansen. Martinus Nijhoff, Publishers, Boston, pp 1-30, 1986.
18. Jakobsson O, Bergh J. Acral lentiginous malignant melanoma. A case report. *Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery* 20:323-326, 1986.
19. Saksela K, Bergh J, Nilsson K. Amplification of the *N-myc* oncogene in an adenocarcinoma of the lung. *Journal of Cellular Biochemistry* 31:297-304, 1986.
20. Bergh J, Esscher T, Steinholtz L, Nilsson K, Pålman S. Immunocytochemical demonstration of Neuron-Specific Enolase (NSE) in human lung cancers. In: *1986 Year Book of Cancer*. Eds Hickey RC, Saunders GF, Randolph LC, Cumley RW, pp 440-442, 1986.
21. Norheim I, Wilander E, Öberg K, Theodorsson-Norheim E, Lundqvist M, Lindgren P-G, Bergh J. Tachykinin production by carcinoid tumours in culture. *European Journal of Cancer & Clinical Oncology* 23:689-695, 1987.
22. Betsholtz C, Bergh J, Bywater M, Pettersson M, Johnsson A, Heldin C-H, Ohlsson R, Knott T, Scott J, Bell G, Westermarck B. Expression of multiple growth factors in a human lung cancer cell line. *International Journal of Cancer* 39:502-507, 1987.
23. Funa K, Steinholtz L, Nöu E, Bergh J. Increased expression of *N-myc* in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. *American Journal of Clinical Pathology* 88:216-220, 1987.
24. Bergh J. Tumörtillväxt och tumörheterogenitet. *Lungcancer - cellulära mekanismer*. Draco. Swedish association for Lung Medicine: 49-63, 1987.
25. Bergh J, Björk P, Westlin J-E, Nilsson S. Expression of an estramustine-binding associated protein in human lung cancer cell lines. *Cancer Research* 48:4615-4619, 1988.
26. Brezicka T, Olling S, Nilsson O, Bergh J, Holmgren J, Sörenson S, Yngvason F, Lindholm L. Immunohistological detection of Fucosyl-G<sub>m1</sub> ganglioside in human lung cancer and normal tissues with monoclonal antibodies. *Cancer Research* 49:1300-1305, 1989.
27. Nordgren H, Nilsson S, Runn A-C, Pontén J, Bergh J. Histopathological and immunohistochemical analysis of lung tumors: Description of a convenient technique for use with fine needle biopsy. *APMIS* 97:136-142, 1989.

28. Söderdahl G, Betsholz C, Johansson A, Nilsson K, Bergh J. Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. *International Journal of Cancer* 41:636-641, 1988.
29. Bergh J, Arnberg H, Eriksson B, Lundqvist G. The release of chromogranin A and B like activity from human lung cancer cell lines. A potential marker for a subset of small cell lung cancer. *Acta Oncologica* 28:651-653, 1989.
30. von Schoultz E, Lundblad D, Bergh J, Grankvist K, Kourtopoulos H, Henriksson R. Characterization of the cytotoxic effect of estramustine on malignant glioma. *Proceedings of the 15th international congress of chemotherapy, Istanbul, Turkey, July 19-24, 1987*, pp 844-846.
31. Nöu E, Brodin O, Bergh J. A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens. *Cancer* 62:1079-1090, 1988.
32. Wilking N, Rotstein S, Bergh J. Nya rön om bröstcancer - prevention, diagnostik och endokrin terapi. *Läkartidningen* 85:2735-2736, 1988.
33. Bergh J, Söderdahl G. Human non-small cell lung cancer cell lines express platelet derived- and transforming growth factor genes and induce stroma formation in nude mice tumors. *Lung Cancer* 4:179-185, 1988.
34. von-Schoultz E, Lundblad D, Bergh J, Grankvist K, Henriksson R. Estramustine binding protein and anti proliferative effect of estramustine in human glioma cell lines. *British Journal of Cancer* 58:326-329, 1988.
35. Nolte H, Gjedde S, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen HT. Phase II study of tauromustine in disseminated malignant melanoma. *European Journal of Cancer of Clinical Oncology* 25:655-657, 1989.
36. Nettelbladt O, Bergh J, Schenholm M, Tengblad A, Hällgren R. Accumulation of hyaluronic acid in the alveolar interstitial tissue in Bleomycin-induced alveolitis. *The American review of respiratory disease* 139:759-762, 1989.
37. Bergh J. The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors. *The American Journal of Pathology* 133:434-439, 1988.
38. Hedin G, Ronquist G, Nöu E, Bergh J. L-2,4 diaminobutyric acid as a new therapeutic principle in the management of human bronchial neoplasms. *International Journal of Experimental and Clinical Chemotherapy* 3:23-30, 1990.
39. Bergh J, Nilsson S, Liljedahl C, Lennartsson L, Maripuu E, Blomquist E, Sivolapenko G, Epenetos A, Stavrou D. Indium-märkta monoklonala antikroppar för diagnostik av maligna gliom in vivo? *Behandlingsmöjligheter i framtiden med yttriumkonjugerade antikroppar. Läkartidningen* 87:373-375, 1990.
40. Nöu E, Steinholtz L, Bergh J, Nilsson K, Pålman S. Neuron-specific enolase (NSE) as follow-up marker in small cell bronchial carcinoma. A prospective study in an unselected series. *Cancer* 65:1380-1385, 1990.

41. Bergh J, Nilsson S, Liljedahl C, Maripuu E, Sivolapenko G, Epenetos A, Stavrou D. Radioimaging of human malignant gliomas using indium-labelled monoclonal antibodies. *Nuclear Medicine Communications* 11:437-444, 1990.
42. Rabbitts P, Douglas J, Daly M, Sundaresan V, Fox B, Haselton P, Wells F, Albertson D, Waters J, Bergh J. Frequency and extent of allelic loss in the short arm of chromosome 3 in nonsmall-cell lung cancer. *Genes, chromosomes & cancer* 1:95-105, 1989.
43. Esscher T, Bergh J, Steinholtz L, Nöu E, Nilsson K, Pålman S. Neuron-specific enolase in small-cell carcinoma of the lung: The value of combined immunohistochemistry and serum determinations. *Anticancer Research* 9:1717-1720, 1989.
44. Mouridsen HT, Alftan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, Hellsten S, Kjær M, Peterson C, Skovsgård T, Sørensen JB, Tropé C, Aabo K. Current status of epirubicin (farmorubicin) in the treatment of solid tumours. *Acta Oncologica* 29:257-285, 1990.
45. Ljunghall S, Bergh J, Rastad J, Åkerström G. Hypercalcemi och skelettengagemang vid malignitet - uppkomstmekanismer och behandlingsmöjligheter. *Läkartidningen* 86:1991-1993, 1989.
46. Carney D, Berendsen H, Bergh J, Doyle A, Ikegami H, Mattson K, Mulshine J, Wolf M, Woll P. Biological response modifiers in the management of small cell lung cancer: a consensus report. *Lung Cancer* 5:143-145, 1989.
47. Rabbitts P, Bergh J, Douglas J, Collins F, Waters J. A submicroscopic homozygous deletion at the D3S3 locus in a cell line isolated from a small cell lung carcinoma. *Genes, chromosomes & cancer* 2:231-238, 1990.
48. Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca<sup>2+</sup> and resistance modulation by verapamil in absence of P-glycoprotein overexpression. *British Journal of Cancer* 64:1011-1018, 1991.
49. Bergh J, Nilsson S, Liljedahl C, Sivolapenko G, Maripuu E, Stavrou D, Epenetos A. *In vivo* imaging and treatment of human brain tumours utilizing the radiolabelled monoclonal antibody MUC 2-63. *Anticancer Research* 10:655-660, 1990.
50. Bergh J, Nygren P, Larsson R. Mechanisms for acquired cytotoxic drug resistance in human small cell lung cancer and the potential utilization of resistance modifiers- a review with focus on in vitro studies. *Lung Cancer* 6:9-15, 1990.
51. Nettelbladt O, Scheynius A, Bergh J, Tengblad A, Hällgren R. Alveolar accumulation of hyaluronan and alveolar cellular response in bleomycin-induced alveolitis. *European Respiratory Journal* 4:407-414, 1991.
52. Bergh J. Gene amplification in human lung cancer - The *myc* family genes and other proto-oncogenes and growth factor genes. *The American review of respiratory disease* 142:20-26, 1990.
53. Geijer T, Bergh J, Terenius L. Expression of preprodynorphin in human small cell lung carcinoma cell lines. *Regulatory Peptides* 34:181-188, 1991.

54. Daly MC, Douglas JB, Bleeheh NM, Hastleton P, Twentyman PR, Sundaresan V, Carritt B, Bergh J, Rabbitts PH. An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. *Genomics* 9:113-119, 1991.
55. Egyházy S, Bergh J, Hansson J, Karran P, Ringborg U. Carmustine-induced toxicity, DNA crosslinking and O<sup>6</sup>-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. *European Journal of Cancer* 27:1658-1662, 1991.
56. Bergh J. Monoclonal antibodies for therapy of human malignant tumours. Invited paper, *Eur J Surg S* 561:59-64, 1991.
57. Lindman H, Taube A, Bergh J. Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-Glycoprotein. *Anticancer Research* 14:363-366, 1994.
58. Larsson R, Bergh J, Nygren R. Combination of cyclosporin a and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of MDR in SCLC cell lines selected for resistance to doxorubicin. *Anticancer Research* 11:455-460, 1991.
59. Bergh J. Biological response modifiers in regional cancer therapy. Invited paper, *European Journal of Surgery* 561:87-90, 1991.
60. Bergh J, Nilsson S, Sivolapenko G, Maripuu E, Stavrou D, Epenetos A. Localization and immunohistochemistry of human gliomas using the MUC 2-63 antibody. In: *Monoclonal antibodies, applications in clinical oncology*. Ed: AA Epenetos. Chapman & Hall, pp 245-251, 1991.
61. Forsberg K, Bergh J, Westermark B. Expression of functional PDGF b receptors in a human large-cell lung-carcinoma cell line. *International Journal of Cancer* 55:556-560, 1993.
62. Bergh J, Tötterman T, Termander B, Strandgarden K, Gunnarsson PO, Nilsson B. The first clinical pilot study of roquinimex (Linomide<sup>®</sup>) in cancer patients with special focus on immunological effects. *Cancer Investigation* 15:204-211, 1997.
63. Öberg F, Hult N, Bjare U, Ivhed I, Kivi S, Bergh J, Larsson L-G, Sundström C, Nilsson K. Characterization of a U-937 subline which can be induced to differentiate in serum-free medium. *International Journal of Cancer* 50:153-160, 1992.
64. Drabkin H, Mendez MJ, Rabbitts PH, Varkony T, Bergh J, Schlessinger J, Erickson P, Gemmill RM. Characterization of the submicroscopic deletion in the small-cell lung carcinoma cell line U-2020. *Genes, chromosomes & cancer* 5:67-74, 1992.
65. de la Torre M, Wells AF, Bergh J, Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. *Human Pathology* 24:1294-1297, 1993.
66. Larsson R, Nygren P, Bergh J. Experimentell farmakologisk tumörbehandling med klinisk potential. *Läkartidningen* 88:4441-4444, 1991.

67. Heldin N-E, Usuki K, Bergh J, Westermark B, Heldin C-H. Differential expression of platelet-derived endothelial cell growth factor thymidine phosphorylase in human lung carcinoma cell lines. *British Journal of Cancer* 68:708-711, 1993.
68. de la Torre M, Hao X-Y, Larsson R, Nygren P, Tsuruo, Mannervik B, Bergh J. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. *Anticancer Research* 13:1425-1430, 1993.
69. Westlin J-E, Snook D, Nilsson S, Husin S, Enblad P, Stavrou S, Epenetos A, Bergh J. Intravenous and intratumoural therapy on patients with malignant gliomas with <sup>90</sup>Yttrium labelled monoclonal antibody MUC 2-63. Chapman & Hall, pp 17-26, 1993.
70. Bergh J, Larsson R, Nygren P. Resistance to chemotherapeutic drugs in human lung cancer: Is circumvention possible? *Lung Cancer* 9:307-316, 1993.
71. Larsson R, Fridborg H, Csoka K, Bergh J, Nygren P. Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. *Anticancer Research* 12:1581-1586, 1992.
72. Bergh J, Rabbitts P. *Biology of human lung cancer*. Ed: F.R. Hirsch pp 49-60, 1993.
73. Brodin O, Arnberg H, Bergh J, Nilsson S. Increased radioresistance of an in vitro transformed human small cell lung cancer cell line. *Lung Cancer* 12:183-198, 1995.
74. Hao XY, Castro V, Bergh J, Sundström B, Mannervik B. Isoenzyme-specific quantitative immunoassays for cytosolic glutathione transferases and measurement of the enzymes in the blood plasma from cancer patients and in tumor cell lines. *Biochimica et Biophysica Acta* 1225:223-230, 1994.
75. Pestana S, Björklund G, Larsson R, Nygren P, Nilsson K, Bergh J. Effects of interferons and tumour necrosis factor- $\alpha$  on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. *Acta Oncologica* 35: 473- 478, 1996.
76. de la Torre M, Nygren P, Larsson R, Lindgren A, Tsuruo T, Bergh J. Expression of the 85-kd membrane protein in primary human breast cancer: Relationship to hormone receptor levels, DNA ploidy, and tumor grade. *Human Pathology* 26:180-185, 1995.
77. Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Phase I study of tauromustine administered in a weekly schedule. *European Journal of Cancer* 29A:1901-1902, 1993.
78. Liljegren G, Holmberg L, Adami H-O, Westman G, Graffman S, Bergh J and the Uppsala-Örebro breast cancer study group. Sector resection with or without postoperative radiotherapy for stage I breast cancer: Five-year results of a randomized trial. *Journal of the National Cancer Institute* 86:717-722, 1994.
79. Jansson T, Westlin J-E, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? *Journal of Clinical Oncology* 13:1470-1477, 1995.

80. Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Phase II study of tauromustine in disseminated malignant melanoma. *European Journal of Cancer* 30A:566, 1994.
81. Hao X-Y, Bergh J, Brodin O, Hellman U, Mannervik B. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. *Carcinogenesis* 15:1167-1173, 1994.
82. Fjällskog M-L, Frii L, Bergh J. Paclitaxel-induced cytotoxicity - the effects of cremophor EL (castor oil) in two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. *European Journal of Cancer* 30A:687-690, 1994.
83. Nygren P, Fridborg H, Csoka K, Sundström C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B, Larsson R. Detection of tumor-specific cytotoxic drug activity *in vitro* using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. *International Journal of Cancer* 56:715-720, 1994.
84. Liljegren G, Lindgren A, Bergh J, Nordgren H, Tabár L, Holmberg L. Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. *Annals of Oncology* 8:235-241, 1997.
85. Petrén-Mallmin M, Andréasson I, Ljunggren Ö, Ahlström H, Bergh J, Antoni G, Långström B, Bergström M. Skeletal metastases from breast cancer: uptake of <sup>18</sup>F-fluoride measured with positron emission tomography in correlation with CT. *Skeletal Radiology* 27:72-76, 1998.
86. Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J, Karlsson MO. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. *Journal of Clinical Oncology* 14:1581-1588, 1996.
87. Bergenheim AT, Hartman M, Bergh J, Ridderheim P-Å, Henriksson R. Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells. *Journal of Neuro-Oncology* 22:45-53, 1994.
88. Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A, Lönnerholm G, Jakobsson Å, Olsen L, Kristensen J, Larsson R. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. *British Journal of Cancer* 71:478-481, 1995.
89. Fridborg H, Jonsson B, Nygren P, Csoka K, Nilsson K, Öberg G, Kristensen J, Bergh J, Tholander B, Olsen L, Jakobsson Å, Larsson R. Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. *British Journal of Cancer* 70:11-17, 1994.
90. Klominek J, Robert KH, Bergh J, Hjerpe A, Gahrton G, Sundqvist KG. Production of a motility factor by a newly established lung adenocarcinoma cell line. *Anticancer Research* 18:759-767, 1998.

91. de la Torre M, Larsson R, Nygren P, Lindgren A, Bergh J. Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers. *Acta Oncologica* 33:773-777, 1994.
92. Bergenheim T, Björk P, Bergh J, von Schultz E, Svedberg H, Henriksson R. Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. *Cancer Research* 54:4974-4979, 1994.
93. Bergh J. High dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer - A review. *Acta Oncologica* 34:669-674, 1995.
94. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. *Nature Medicine* 1:1029-1034, 1995.
95. de la Torre M, Heldin P, Bergh J. Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers. *Anticancer Research* 15:2791-2796, 1995.
96. Westman G, Ahlgren J, Jansson T, Bergh J. Cross-comparison of two quality of life instruments used in a randomized study of combination chemotherapy in advanced breast cancer. *Acta Oncologica* 38:567-572, 1999.
97. Gustavsson B, Hermansson A, Andersson AC, Grimelius L, Bergh J, Westermark B, Heldin NE. Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. *Molecular and Cellular Endocrinology* 121:143-151, 1996.
98. Davies SL, Bergh J, Harris AL, Hickson ID. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. *British Journal of Cancer* 75:816-821, 1997.
99. de la Torre M, Larsson R, Nygren P, Lindgren A, Hao X-Y, Mannervik B, Bergh J. Differential expression of glutathione S-transferase Pi in normal, preneoplastic and neoplastic human breast tissue. *Cell Vision* 3:11-15, 1996.
100. Heldin P, de la Torre M, Ytterberg D, Bergh J. Differential synthesis and binding of hyaluronan by human breast cancer cell lines: Relationship to hormone receptor status. *Oncology Reports* 3:1011-1016, 1996.
101. Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. *Cancer Research* 55:3908-3914, 1995.
102. Liljegren G, Karlsson G, Bergh J, Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. *Annals of Oncology* 8:757-763, 1997.
103. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. *Journal of the National Cancer Institute* 88:173-182, 1996.



104. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings. *Journal of Clinical Oncology* 13:2745-2751, 1995.
105. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. *Journal of the National Cancer Institute* 88:1543-1549, 1996.
106. Bergh J. Radioimmunotherapy using <sup>125</sup>I and <sup>131</sup>I labelled monoclonal antibody A33. *Tumor Targeting* 1:289-290, 1995.
107. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Suramin in non-small cell lung cancer and advanced breast cancer - Two parallel phase II studies. *Acta Oncologica* 36:171-174, 1997.
108. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. *The Lancet* 348:1189-1196, 1996.
109. Williams C, Norberg T, Ahmadian A, Pontén F, Bergh J, Lundeberg J, Uhlén M. Assessment of sequence-based p53 analysis in human breast cancer; messenger RNA in comparison with genomic DNA targets. *Clinical Chemistry* 44:455-462, 1998.
110. Norberg T, Jansson T, Sjögren S, Mårtensson C, Andréasson I, Fjällskog M-L, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. *Acta Oncologica Suppl 5* 35:96-102, 1996.
111. Bergh J. Ökade kunskaper om lungcancerbiologi. *Läkartidningen* 94:1489-1492, 1997.
112. Sirzén F, Heiden T, Nilsson A, Bergh J, Skog S, Lewensohn. Characterisation of the G1/S cell cycle checkpoint defect in lung carcinoma cells with different intrinsic radiosensitivities. *Anticancer Research* 17:3381-3386, 1997.
113. Heppell-Parton AC, Nacheva E, Carter NP, Bergh J, Ogilvie D, Rabbitts P. Elucidation of the mechanism of homozygous deletion of 3p12~13 in the U2020 cell line reveals the unexpected involvement of other chromosomes. *Cancer Genetics and Cytogenetics* 111:105-110, 1999.
114. Jansson T, Lindman H, Nygård K, Dahlgren CV, Montelius A, Öberg-Kreuger C, Asplund S, Bergh J. Radiotherapy of breast cancer after breast conserving surgery: An improved technique using mixed electron-photon beams with a multileaf collimator. *Radiotherapy and Oncology* 46:83-89, 1998.
115. Sirzén F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities. *Anticancer Research* 18:695-699, 1998.
116. Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson N-O, Malmström P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients. *Annals of Oncology* 9:403-411, 1998.

117. Bergh J. Dose intensity in patients with metastatic breast cancer - Time for novel thoughts? Editorial, *Annals of Oncology* 8:109-110, 1997.
118. Bergh J. Determination and use of p53 in the management of cancer patients with special focus on breast cancer - A review. J.G.M. Klijn, Ed. *Prognostic and Predictive Value of p53*. European School of Oncology Scientific Updates 1:35-50, 1997.
119. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. *Clinical Pharmacology & Therapeutics* 63:11-25, 1998.
120. Bergh J. Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation? Editorial Comment, *Journal of the National Cancer Institute* 89:605-607, 1997.
121. Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. *Journal of Clinical Oncology* 16:462-469, 1998.
122. Lindman H, Wiklund T, Holte H, Ljungman P, Blomqvist C, Kvalheim G, Bengtsson M, Höglund M, Wilking N, Bergh J. FEC mobilised stem cells for high dose therapy in breast cancer patients. *Acta Oncologica* 38:239-245, 1999.
123. Karlsson Y, Malmström P, Hatschek T, Fornander T, Söderberg M, Bengtsson N-O, Jansson T, Sjöberg S, Bergh J. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. *Cancer* 83:936-947, 1998.
124. Vaghef H, Nygren P, Edling C, Bergh J, Hellman B. Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. *Mutation Research* 395:127-138, 1997.
125. Boström Å, Sjölin-Forsberg G, Wilking N, Bergh J. Radiation recall. Another call with tamoxifen. *Acta Oncologica* 38:955-959, 1999.
126. Ljungman P, Björkstrand B, Fornander T, Höglund M, Juliusson G, Lindman H, Malmström A, Rotstein S, Söderberg M, Wilking N, Villman K, Bergh J. High dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. *Bone Marrow Transplantation* 22:445-448, 1998.
127. Wärnberg F, Nordgren H, Bergh J, Holmberg L. Ductal carcinoma *in situ* of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. *European Journal of Cancer* 35, 714-720, 1999.
128. Bergh J. Analysis of the p53 status of tumours: an overview of methods. In: *Methods in Molecular Medicine – Cytotoxic Drug Resistance Mechanisms*. Eds Brown R, Böger-Brown U, Humana Press, Totowa, New Jersey, pp 179-199, 1999.
129. Norberg T, Lennerstrand J, Inganäs M, Bergh J. Comparison between p53 protein measurement using the luminometric immunoassay and immunohistochemistry with

detection of p53 gene mutations using cDNA sequencing in human breast tumours. *International Journal of Cancer* 79:376-383, 1998.

130. Ciray I, Åström G, Andréasson I, Edekling T, Hansen J, Bergh J, Ahlström H. Evaluation of new sclerotic metastases in breast cancer patients during treatment. *Acta Radiologica* 41:178-182, 2000.
131. von Heideman A, Sandström M, Csoka K, Tholander B, Larsson R, Bergh J, Nygren P. Evaluation of drug interactions in the established FEC regimen in primary cultures of tumor cells from patients. *Annals of Oncology* 11:1301-1307, 2000.
132. Bergh J. Tailored chemotherapy to equal toxicity - is it possible? Senn H-J, Gelber R, Goldhirsch A, Thürlimann B (Eds.). In *Adjuvant Therapy of Primary Breast Cancer*. Springer-Verlag, Berlin, Heidelberg, New York, p. 328 - 340, 1998.
133. Aalto Y, Forsgren S, Kjörrell U, Bergh J, Franzén L, Henriksson R. Enhanced expression of neuropeptides in human breast cancer cell lines following irradiation. *Peptides* 19:231-239, 1998.
134. Wärnberg F, Bergh J, Holmberg L. Prognosis in women with carcinoma in situ of the breast. A population-based cohort study in Sweden. *Cancer epidemiology Biomarkers & Prevention* Vol 8, 769-774, September 1999.
135. Bergh J. Importance of p53 in the diagnosis and treatment of cancer. 23rd ESMO Congress, Athens Greece, p. 179-186, 1998.
136. Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, Roberts I, James L, Cahn A, Bench A, Douglas J Minna J, Sekido Y, Lerman M, Latif F, Bergh J, Li H, Lowe N, Ogilvie D, Rabbitts P. Homozygous deletions at 3p12 in breast and lung cancer. *Oncogene* 17:1723-1729, 1998.
137. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson N-O, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Andersson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. *European Journal of Cancer*, 35, No 8, 1194-1201, 1999.
138. Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabár L, Nordgren H, Adami H O and the Uppsala-Örebro breast cancer study group. Ten-year results following sector resection with or without postoperative radiotherapy for breast cancer stage I: a randomized trial. *Journal of Clinical Oncology* Vol 17, No 8 (August), pp 2326-2333, 1999.
139. Hultborn R, Johansson-Terje I, Bergh J, Glas U, Hallsten L, Hatschek T, Holmberg E, Idestrom K, Norberg B, Ranstam J, Söderberg M, Wallgren U-B. Second-line endocrine treatment of advanced breast cancer - a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide. *Acta Oncologica* 35, suppl 5: short report page 75, 1996.
140. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *The Lancet* 351:1451-1467, 1998.

141. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. *The Lancet* 352:930-942, 1998.
142. Sirzén F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. *Lung Cancer* 22:1-13, 1998.
143. Linderholm B, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. *Cancer Research* 61 (5):2256-60, 2001.
144. Dummer R, Bergh J, Karlsson Y, Horowitz J A, Mulder N, Ten Bokkel Huinink D, Burg G, Hofbauer G, Osanto S. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumours. *Cancer Gene Therapy* 7:1069-1076, 2000.
145. Thurfjell G, Jansson T, Nordgren H, Bergh J, Lindgren A, Thurfjell E. Local breast cancer recurrence caused by mammographically guided punctures? *Acta Radiologica* 41:435-440, 2000.
146. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Pharmacokinetic models for the saturable distribution of paclitaxel. *Drug Metabolism & Disposition* 27 (10):1220-1223, 1999.
147. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. *Endocrine-Related Cancer* 6:51-59, 1999.
148. Bergh J. Is there a role for intensive therapy in breast cancer? *Acta Oncologica* 38: suppl 13:37-46, 1999.
149. Lindahl T, Norberg T, Åström G, Sjögren S, Bergh J. Cellular and tissue markers in solid tumors. Eds: Bronchud M, Foote MA, Peters WP, Robinson MO. Humana Press. In: *Principles of molecular oncology*, pp: 95-110. 2000.
150. Ahlgren J, Risberg B, Villman K, Bergh J. Angiogenesis in invasive breast carcinoma – a prospective study of tumor heterogeneity. *European Journal of Cancer* 38:64-69, 2002.
151. Norberg T, Klaar S, Kärf G, Nordgren H, Holmberg L, Bergh, J. Increased p53 mutation frequency during tumor progression – results from a breast cancer cohort. *Cancer Research* 61 (22):8317-8321, 2001.
152. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *The Lancet* 355:1757-1770, 2000.
153. Hakamies-Blomqvist L, Luoma M-L, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P-O, Blomqvist C. Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group. *European Journal of Cancer* 36:1411-1417, 2000.

154. Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Öhd J, Rudenstam C-M, Gustavsson B, Bergh J. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. *Annals of Oncology* 16:743-748, 2005.
155. Lindahl T, Engel G, Ahlgren J, Klaar S, Bjöhle J, Lindman H, Andersson J, von Schultz E, Bergh J. Can axillary dissection be avoided by improved molecular biological diagnosis? *Acta Oncologica* 3:319-326, 2000.
156. Lampic C, Thurffjell E, Bergh J, Sjödén P-O. Short- and long-term anxiety and depression in women recalled after breast cancer screening. *European Journal of Cancer* 37:463-469, 2001.
157. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson N-O, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N, for the Scandinavian Breast Group 9401 study. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. *The Lancet* 356:1384-91, 2000.
158. Erselcan T, Kairemo KJA, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, Bergh J, Joensuu H. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. *British Journal of Cancer* 82:777-781, 2000.
159. Pontén F, Lindman H, Boström Å, Berne B, Bergh J. Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. *Journal of the National Cancer Institute* 93:128-133, 2001.
160. Boström Å, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind randomized study. *Radiotherapy and Oncology* 259, 3:257-65, 2001.
161. Ahlgren J, Holmberg L, Bergh J, Liljegren G. Five-node biopsy of the axilla: an alternative to axillary dissection of level I-II in operable breast cancer. *European Journal of Surgical Oncology* 28:97-102, 2002.
162. Wärnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ. A population-based case-control study in Sweden. *Cancer Epidemiology, Biomarkers & Prevention* 10:495-499, 2001.
163. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer? Commentary for *The Lancet* 355:944-945, 2000.
164. Ciray I, Lindman H, Åström G, Bergh J, Ahlström H. Early response of breast cancer bone metastases to chemotherapy evaluated MR imaging. *Acta Radiologica* 42:198-206, 2001.
165. Ciray I, Lindman H, Åström G, Wanders A, Bergh J, Ahlström H. Effect of granulocyte colony-stimulating factor (G-CSF)-supported chemotherapy on MR imaging of normal red bone marrow in breast cancer patients with focal bone metastases. *Acta Radiologica* 44:472-484, 2003.
166. Sjöström J, Blomqvist C, Heikkilä P, von Boguslawski K, Räisänen-Sokolowski A, Bengtsson N-O, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela

- E. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. *Clinical Cancer Research* 6:3103-3110, 2000.
167. Norberg T, Klaar S, Lindqvist L, Lindahl T, Ahlgren J, Bergh J. Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers. *Clinical Chemistry* 47:821-828, 2001.
168. Bergh J, Holmqvist M. Who should not receive adjuvant chemotherapy – international databases. *JNCI Monographs* (30):103-108, 2001.
169. Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow supported high-dose chemotherapy with cyclophosphamide, thiothepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. *Journal of Clinical Oncology* 21:6359-3664, 2003.
170. Hernberg M, Virkkunen P, Maasilta P, Keyriläinen J, Blomqvist C, Bergh J, Wiklund T. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. *International Journal of Radiation Oncology, Biology, Physics* 52:128-36, 2002.
171. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. *Carcinogenesis* 25: 375-80, 2004.
172. Hakamies-Blomqvist C, Luoma M-L, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C. Timing of quality of life (QoL) assessments as a source of error in oncological trials. *The Journal of Advanced Nursing* 35:709-16, 2001.
173. Sjöström J, Bergh J. How apoptosis is regulated, and what goes wrong in cancer. *BMJ* 322: 1538-9, 2001.
174. Bergh J, Jönsson P-E, Glimelius B, Nygren P for the SBU-group. A systemic overview of chemotherapy effects in breast cancer. *Acta Oncologica* 40 (no 2/3): 253-281, 2001.
175. Sundby Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andresen A, Skovlund E, Bergh J, Hall C. Effects of dose-intensive chemotherapy and radioth Breast Cancer Research and Treatment 67:235-44, 2001.
176. Lidbrink E, Bergh J. Chemotherapy of breast cancer – can we improve outcome and decrease toxicity by tailoring therapy. *American Journal of Cancer Research* 1:165-171, 2002.
177. Bergh J. Dose escalation in adjuvant chemotherapy – Is this a dead end? *Breast Cancer Online*, Vol 5, issue 4, 2002. On [www.bco.org](http://www.bco.org).
178. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund H, Högberg T, Janunger K-G, Jönsson P-E, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types –summary and conclusions. *Acta Oncologica* 40 (no 2/3): 135-154, 2001.

179. Bergh J. Use of G-CSF and GM-CSF in patients with solid tumours. Eds: Ahlqvist Raastad J, Alvan G, Bredal W, Wesenberg GR. Läkemedelsverket/Medical Products Agency. In: Granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoetin in haematology and oncology, pp 78-103, 2001.
180. Berglund Å, Glimelius B, Bergh J, Brodin O, Fjällskog M-L, Hagberg H, von Heideman A, Larsson R, Tholander B, de la Torre M, Åström G, Öberg K, Parö G, Nygren P. Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial. *Medical Oncology* 19(3):151-9, 2002.
181. Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson N-O, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. *European Journal of Cancer* 38:535-542, 2002.
182. Amini RM, Berglund M, Rosenquist R, Von Heideman A, Lagercrantz S, Thunberg U, Bergh J, Sundstrom C, Glimelius B, Enblad G. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. *Leukemia & Lymphoma* 43:2179-89, 2002.
183. Lampic C, Thurfjell E, Bergh J, Carlsson M, Sjödén P-O. Life values before versus after a breast cancer diagnosis. *Research in Nursing & Health* 25:89-98, 2002.
184. Jönsson-Videsäter K, Andersson G, Bergh J, Paul C. Doxorubicin-resistant, MRP1 expressing U-1285 cells are sensitive to idarubicin. *Therapeutic Drug Monitoring* 25 (3):331-339, 2003.
185. Bergh J. Is pharmacokinetically guided chemotherapy dosage a better way forward? *Annals of Oncology* 13: 343-344, 2002.
186. Sandström M, Lindman H, Nygren P, Lidbrink D, Bergh J, Karlsson MO. Model describing the relationship between pharmacokinetics and haematological toxicity of the epirubicin-docetaxel regimen in breast cancer patients. *Journal of Clinical Oncology* 23:413-21, 2005.
187. Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L, Petterson-Sköld D, Sverrisdottir A, Söderberg M, Klaar S, Bergh J. A population based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin®) on a named patient basis in Sweden. *Acta Oncologica* 3:276-281, 2002.
188. Andersson J, Linderholm B, Bergh J, Elmberger G. HER-2/neu (c-erbB-2) Evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with a special focus on intratumor heterogeneity and comparison of invasive and in situ components. *Applied Immunohistochemistry & Molecular Morphology* 12:14-20, 2004.
189. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer A-M, Krasilnikoff K, Bergh J, Karlsson M O, Lönnebo A, Ahlgren J. A Phase I study of CHS 828 in patients with solid tumor malignancy. *Clinical Cancer Research* 8:2843-50, 2002.
190. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G. Monitoring of disseminated tumor cells in bone marrow in high-risk

breast cancer patients treated with high-dose chemotherapy. *International Journal of Cancer*, 118:2877-81, 2006.

191. Lindman H, Astrom G, Ahlgren J, Villman K, Blomqvist C, Nygren P, Bergh J. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. *Acta Oncologica* 46(2):165-71, 2007.
192. Henningsson A, Sparreboom A, Sandström M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. *European Journal of Cancer* 39:1105-1114, 2003.
193. Smeds J, Wärnberg F, Norberg T, Nordgren H, Holmberg L, Bergh J. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity. *Acta Oncologica* 44:41-49, 2005.
194. Linderholm B, Norberg T, Bergh J. Sequencing of the tumour suppressor gene TP53. *Methods in molecular medicine* 120:389-401, 2006.
195. Egyházi S, Bjöhle J, Skoog L, Huang F, Borg A-L, Frostvik Stolt M, Hägerström T, Ringborg U, Bergh J. Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. *Clinical Chemistry* 50:975-976, 2004.
196. Lampic C, Thurffjell E, Bergh J, Carlsson M, Sjödén P-O. Attainment and importance of life values among patients with primary breast cancer. *Cancer Nursing* 26:295-304, 2003.
197. Linderholm B, Lindahl T, Öhd J, Bergh J. Cellular and tissue markers in solid tumors. Eds: Bronchud M, Foote MA, Giaccone G, Olufunmilayo O, Workman P. Humana Press. In: *Principles of molecular oncology*, second edition, pp: 181-213. 2004.
198. Wengström Y, Forsberg C, Näslund I, Bergh J. Quantitative assessment of skin erythema due to radiotherapy – evaluation of different measurements. *Radiotherapy and Oncology* 72:191-197, 2004.
199. Pawitan Y, Bjöhle J, Wedren S, Humphreys K, Skoog L, Huang F, Amler L, Shaw P, Hall P, Bergh J. Gene expression profiling for prognosis using Cox regression. *Statistics in Medicine* 23:1767-80, 2004.
200. Bergh J. Best use of adjuvant systemic therapies II, chemotherapy aspects dose of chemotherapy-cytotoxicity, duration and responsiveness. *The Breast*, special issue: 8<sup>th</sup> International Conference on Primary care. *The Breast* 12:529-37, 2003.  
<http://authors.elsevier.com/sd/article/S0960977603001620>
201. Pawitan Y, Bjöhle J, Amler L, Borg A-L, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu E, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw P, Smeds J, Skoog L, Wedrén S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Research* 7: R953-R964, 2005.
202. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of



the randomised trials. *The Lancet* 365:1687-1717, 2005.

<http://www.ctsu.ox.ac.uk/~ebctcg/info/>

203. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *The Lancet* 366:2087-2106, 2005.
204. Wilczek B, von Schoultz E, Bergh J, Eriksson E, Larsson SA, Jacobsson H. Early assessment of neoadjuvant chemotherapy by FEC-courses of locally advanced breast cancer using <sup>99m</sup>Tc-MIBI. *Acta Radiologica* 44:284-287, 2003.
205. Luoma M-L, Hakamies-Blomqvist L, Sjöström J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson N-O, Bergh J, Malmström P, Valvere V, Tennvall L, Blomqvist C. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. *European Journal of Cancer* 39:1370-1376, 2003.
206. Praga C, Bergh J, Bliss J, Bonnetterre J, Cesana B, Coombes R C, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. *Journal of Clinical Oncology* 23:4179-91, 2005.
207. Bergh J. Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? Commentary for *The Lancet* 362:183-184, 2003.
208. Linderholm B, Karlsson E, Klaar S, Lindahl T, Borg A-L, Elmberg G, Bergh J. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. *European Journal of Cancer* 40:2417-2423, 2004.
209. Bergh J. Adjuvant chemotherapy in breast cancer patients with hormone receptor-positive (responsive) disease: focus on premenopausal patients. Ingle J, Dowsett M (Eds). In *Advances in endocrine therapy of breast cancer*. Marcel Dekker, New York, NY, p127-136, chapter 9, 2004.
210. Linderholm B, Bergh J. Weekly taxanes – a leap forward or a minute progress? *Acta Oncologica* 47:5-7, 2004.
211. Ehrsson H, Eksborg S, Bergh J. Analytical methods: development, validation, and clinical applicability. Figg, WD and McLeod, HL (Eds). In *Handbook of anticancer pharmacokinetics and pharmacodynamics*. Humana Press Inc, Totowa, NJ, p 177-4, chapter 6, 2004.
212. Linderholm B, Lindh B, Beckman L, Erlanson M, Edin K, Tavelin B, Bergh J, Grankvist K, Henriksson R. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. *Clinical Breast Cancer* 4:340-347, 2003.
213. Hall P, Ploner A, Bjöhle J, Huang F, Lin C-Y, Liu E, Miller L, Nordgren H, Pawitan Y, Shaw P, Skoog L, Smeds J, Wedren S, Öhd J, Bergh J. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. *BMC Medicine* 4:16, 2006.

214. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami H-O, Hall P. Genetic implications of bilateral breast cancer: a population based cohort study. *The Lancet Oncology* 6:377-382, 2005.
215. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu E, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proceedings of the National Academy of Sciences of the United States of America* 102:13550-13555, 2005.
216. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. Topoisomerase II $\alpha$  gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer. Scandinavian breast group trial 9401. *Journal of Clinical Oncology* 24:2428-2436, 2006.
217. Kellokumpu-Lehtinen P, Bergh J, Salminen E, Wiklund T, Lehtinen S, Aronen P, et al. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study. *Acta Oncologica* 46:146-52, 2007.
218. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleu P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz A-L, Fiche M, Brisken C, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumors by microarray analysis. *Oncogene* 24:4660-4671, 2005.
219. Nordenskjöld B, Rosell J, Rutqvist LE, Malmström P-O, Bergh J, Bengtsson N-O, Hatschek T, Wallgren A, Carstensen J. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. *Journal of the National Cancer Institute* 97 1609-1610, 2005.
220. Ploner A, Miller LD, Hall P, Bergh J, Pawitan Y. Correlation test to assess low-level processing of high-density oligonucleotide microarray data. *BMC Bioinformatics* 6:80-99, 2005.
221. Lin C Y, Strom A, Li Kong S, Kietz S, Thomsen J S, Tee J B, Vega V B, Miller L D, Smeds J, Bergh J, Gustafsson J A, Liu E T. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. *Breast Cancer Research* 9: R25, 2007.
222. Kronenwett U, Ploner A, Zetterberg A, Bergh J, Hall P, Auer G, Pawitan Y. Genomic instability and prognosis in breast carcinomas. *Cancer Epidemiology, Biomarkers & Prevention* 9: 1630-5, 2006.
223. Albain K, de la Garza Salazar J, Pienkowski, Aapro M, Bergh J, Caleffi M, Coleman R, Eierman W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi G. Reducing the global breast cancer burden: the importance of patterns of care research. *Clinical Breast Cancer* 5:412-20, 2005.
224. Bergqvist J, Elmberger G, Öhd J, Linderholm B, Bjöhle J, Hellborg H, Nordgren H, Borg AL, Skoog L, Bergh J. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. *European JB Publication list* November 20, 2020

Journal of Cancer April 42:1104-1112, 2006.

225. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Urhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale A-L. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. *Clinical Cancer Research* 12:1157-61, 2006.
226. Smeds J, Miller L, Bjöhle J, Hall P, Klaar S, Liu E, Pawitan Y, Ploner A, Bergh J. Gene profile and response to treatment. *Annals of Oncology* 16 (suppl 2):ii195-ii202, 2005.
227. Bergh J. Adjuvant chemotherapy for breast cancer– “one fits all”? *The Breast* 6:564-569, 2005.
228. Ivshina A, George J, Senko O, Mow B, Putti TC, Smeds J, Lidahl T, Pawitan Y, Hall P, Nordgren H, Wong JEL, Liu E, Bergh J, Kuznetsov V, Miller L. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. *Cancer Research* 66: 10292-301, 2006.
229. Jacobsson H, Wilczek B, Bergh J, von Schoultz E, Eriksson E, Larsson SA. Different methods for the detection of small changes in uptake between single-photon emission computed tomography (SPECT) examinations: 99mTc-sestamibi in chemotherapy for breast tumours. *Nuclear Medicine Communications* 4: 347-52, 2006.
230. Bergenmar M, Nylén U, Lidbrink E, Bergh J, Brandberg Y. Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. *Acta Oncologica* 45:550-558, 2006.
231. Ejlertsen B, Mouridsen H, Jensen M-B, Bengtsson N-O, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf P, Kamby C, Nielsen D. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. *Journal of Clinical Oncology* 24: 4956-62, 2006.
232. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, van de Vijver M, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *Journal of the National Cancer Institute* 98: 262-272, 2006.
233. Ejlertsen B, Mouridsen H, Jensen M. B, Andersen J, Cold S, Edlund P Ewertz, M Jensen B, Kamby C, Nordenskjold B, Bergh J. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. *European Journal of Cancer* 43: 877-84, 2007.
234. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, Saghathian d'Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ, on behalf of the TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *Journal of the National Cancer Institute* 98:1183-1192, 2006.

235. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J. Basolumental carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. *Clinical Cancer Research* 12:4185-4191, 2006.
236. Arving C, Sjoden P-O, Bergh J, Thalén Lindstrom A, Wasteson E, Glimelius B, Brandberg Y. Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients – a randomised study of nurse versus psychologist interventions. *Patient Education and Counseling* 62:235-243, 2006.
237. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. *Cancer Chemotherapy and Pharmacology* 58:143-156, 2006.
238. Broët P, Kuznetsov VA, Bergh J, Liu E, Miller LD. Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. *Bioinformatics* 22:1477-1485, 2006.
239. Frasar J, Chang EC, Komm B, Lin C-Y, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. *Cancer Research* 66:7334-7340, 2006.
240. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson N-O, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J. Long term follow-up of the SBG 9401 study comparing tailored FEC based therapy vs marrow supported high-dose therapy. *Annals of Oncology* 18: 694-700, 2007.
241. Villman K, Öhd J, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergström D, Ahlgren J. A phase II study of epirubicin, cisplatin- and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. *European Journal of Cancer* 1153-60:43, 2007.
242. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. *Breast Cancer Research* 8, R34, 2006.
243. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. *Nature Medicine* 15:68-74, 2009.
244. Smith I, Procter M, Gelber R, Giullaume S, Feyereislova An, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart M, for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *The Lancet* 369:29-36, 2007.

245. Suter MT, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JGM, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. *Journal of Clinical Oncology* 25:3859-3865, 2007.
246. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale B, Delorenzi M, Zhang Y, d'Assignies M, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C on behalf of the TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clinical Cancer Research* 13: 3207-14, 2007.
247. Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J. Impact of tumour size on axillary involvement and distant dissemination in breast cancer. *British Journal of Cancer* 101, 902-907, 2009.
248. Czene K, Bergqvist J, Hall P, Bergh J. How to treat male breast cancer. *The Breast* 16 S147-S154, 2007.
249. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas genomic grade. *Journal of Clinical Oncology* 25:1239-46, 2007.
250. Bergqvist J, Öhd J, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger G, Hellborg H, Bjöhle J, Borg AL, Skoog, Bergh J. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. *Annals of Oncology* 18:845-850, 2007.
251. Wennmalm K, Calza S, Ploner A, Hall P, Bjöhle J, Klaar S, Smeds J, Pawitan Y, Bergh J. Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes. *Genes Chromosomes Cancer* 46:87-97, 2007.
252. Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami H-O, Dickman P W, Hall P. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. *Journal of Clinical Oncology* 25:4210-16, 2007.
253. Rossmann E, Liljegren A, Bergh J. Breast cancer in man – how to treat? *Breast Cancer Online* vol 10, issue 8, August 2007.  
<http://journals.cambridge.org/action/displayIssue?jid=BCO&volumeId=10&issueId=08#>
254. Maruwge W, D'Arcy P, Folin A, Brijn S, Wejde J, Davis A, Erlandsson F, Bergh J, Brodin B. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-IR-mediated signaling. *OncoTargets and Therapy* 1:67–78, 2009.
255. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. Growth-Inhibitory and Tumor-Suppressive Functions of p53 Depend on Its Repression of CD44 Expression. *Cell* 134(1):62-73, 2008.
256. Arving C, Sjoden PO, Bergh J, Hellbom M, Johansson B, Glimelius B, Brandberg Y. Individual psychosocial support for breast cancer patients: a randomized study of nurse

versus psychologist interventions and standard care. *Cancer Nursing* 30, 3: E10-9, 2007.

257. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) \*. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. *The Lancet* 371:29-40, 2008. \*Member of the Steering Committee.
258. Iristo M, Wiklund T, Wilking N, Bergh J, Brandberg Y. Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. *Acta Oncologica* 50:338-343, 2011.
259. Stragliotto CL, Karlsson K, Lax I, Rutkowska E, Bergh J, Strander H, Blomgren H, Friesland S. A retrospective study of SBRT of metastases in patients with primary sarcoma. *Medical Oncology* 29: 3431-3439, 2012.
260. Wallberg B, von Schoultz E, Bolund C, Bergh J, Wilking N. Hormone replacement therapy after breast cancer - attitudes of women eligible in a randomized trial. *Climacteric* Jul 7, 1-12, 2009.
261. Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. *Annals of Oncology* 19:487-95, 2008.
262. Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegård G, Johansson P, Jonsson B., Kjellen E, Pahlman S, Zackrisson B, Osterborg A. Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations. *Medical Oncology* 24: 267-72, 2007.
263. Nygren P, Blomqvist L, Bergh J, Astrom G. Radiological assessment of tumour response to anti-cancer drugs: Time to reappraise. *Acta Oncologica* 47: 316-8, 2008.
264. Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. *Medical Oncology* published online Jan 7, 2009 (<http://www.springerlink.com/content/w535p0625306k273/>).
265. Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomqvist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre K, Andersson M. The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomized SBG 2000-1 study. *European Journal of Cancer* 45:3198-3204, 2009.
266. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. *Acta Oncologica* 47:740-6, 2008.
267. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin C-H, Bergh J, Brennan D, Jirström K, Östman A. Prognostic significance of stromal PDGF  $\beta$  -receptor expression in human breast cancer. *The American Journal of Pathology* 175, 334-41, 2009.

268. Bergh J. Quo vadis with targeted drugs in the 21<sup>st</sup> century? *Journal of Clinical Oncology* 27:2-5, 2009.
269. Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Bergh J. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. *Breast Cancer Research and Treatment* 125:553-561, 2011.
270. Margolin S, Bengtsson NO, Carlsson L, Edlund P, Fornander T, Hellström M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmström P, Sköld Pettersson D, Söderberg M, Willman K, Bergh J on behalf of the Scandinavian Breast Group Study SBG 2004-1. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. *Acta Oncologica* 50:35-41, 2011.
271. Weichselbaum R, Ishwaran H, Yoon T, Nuyten D, Baker S, Khodarev N, Su A, Shaikh A, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver M, Minna A. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. *Proceedings of the National Academy of Sciences of the United States of America* 105 18490-5, 2008.
272. Wennmalm K, Östman A, Bergh J. Stromal signature identifies basal breast cancers. *Communication, Nature Medicine* 15: 237-8, 2009.
273. Bergh J, Mariani G, Cordoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. *The Breast* 21:507-513, 2012.
274. Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. *The Breast* 18: 259-262, 2009.
275. Howell A, Landberg G, Bergh J. Breast tumour stroma is a prognostic indicator and target for Therapy. Short communication. Available online Jan 2010: <http://breast-cancer-research.com/supplements/11/S3/S16>.
276. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. *Journal of Clinical Oncology* 28:2114-22, 2010.
277. Lindström L, Howell S, Åström G, Wilking U, Lidbrink E, Armstrong A, Karlsson E, Hatschek T, Bergh J. Controversies in the Management of Metastatic Breast Cancer: Biologic Evaluation of Breast Cancer—Should Metastases Be Biopsied? *ASCO Educational 2010*. [http://www.asco.org/ASCOv2/Education+&+Training/Educational+Book?&vmview=edbk\\_detail\\_view&confID=74&abstractID=5](http://www.asco.org/ASCOv2/Education+&+Training/Educational+Book?&vmview=edbk_detail_view&confID=74&abstractID=5)
278. Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J on behalf of the Stockholm Breast Cancer Study Group. Age specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. *Breast Cancer Research and Treatment* DOI.1007/s10549-011 – 1594, 2011.
279. Khoshnoud R, He Q, Sylván M, Khoshnoud A, Ivarsson M, Fornander T, Bergh J, Frisell J, Rutqvist LE, Skog S. The impact of RNA standardization and heterogeneous gene expression

on the results of cDNA array of human breast carcinoma. *International Journal of Molecular Medicine* 25:735-41, 2010.

280. Wilking U, Jönsson B, Wilking N, Bergh J. Trastuzumab use in Breast Cancer (BC) patients in the six Health Care Regions in Sweden. *Acta Oncologica* 49:844-850, 2010.
281. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AV, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjær ST. Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic and Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study. *Journal of Clinical Oncology* 29:264-271, 2011.
282. Eriksson L, Hall P, Czene K, Dos Santos Silva I, McCormack V, Bergh J, Bjohle J, Ploner A. Mammographic density and molecular subtypes of breast cancer. *British J Cancer* 107:18-23, 2012.
283. Howell T, Bergh J. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. *Journal of Clinical Oncology* 28: 4548-4550, 2010.
284. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. *Journal of Translational Medicine* 7;8:53, 2010.
285. Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vitton L, Zhang Y, Massacesi, Sahmoud T, Gianni L. Phase I Trial of Oral mTOR-Inhibitor Everolimus in Combination With Trastuzumab and Vinorelbine in Pre-Treated Patients With HER2-Overexpressing Metastatic. *Breast Cancer Research and Treatment* 125:447-455, 2011.
286. Sverrisdóttir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist LE, Fornander T on behalf of the Stockholm Breast Cancer Study Group. Interaction between goserelin and tamoxifen in a prospective randomized clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. *Breast Cancer Research and Treatment* 128:755-63, 2011.
287. Norenstedt S, Granath F, Ekblom A, Bergh J, Lambe M, Adolfsson J, Warnberg F, Zedenius J, Nilsson IL. Breast cancer associated with primary hyperparathyroidism: a nested case control study. *Clinical Epidemiology* 3:103-106, 2011.
288. Bergh J, Bondarenko IM, Lichinitser MR, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. First-Line Treatment of Advanced Breast Cancer with Sunitinib in Combination with Docetaxel versus Docetaxel Alone – Results of a Prospective, Randomized Phase III Study. *Journal of Clinical Oncology* 30: 921-9, 2012.
289. Early Breast Cancer Trialists' Collaborative Group (EBCTCG\*). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. (\*Jonas Bergh member of the steering committee). *JNCI Monographs* 41:162-77, 2010.
290. Khoshnoud MR, Löfdahl B, Fohlin H, Fornander T, Stål O, Skoog L, Bergh J, Nordenskjöld B. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor



and prediction of the long-term effect of adjuvant tamoxifen. *Breast Cancer Research and Treatment* 126:421-430, 2011.

291. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Dal Lago L, Becette V, Cameron D, Bergh J, Iggo R. Phase III trial (EORTC 10994/BIG 00-01) TP53 Status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer. A randomised phase 3 trial. *The Lancet Oncology* 12:527-539, 2011.
292. Bergh J, Jönsson PE, Lidbrink E, Trudeau M, Eiermann W, Brattström D, Lindemann J, Wiklund F, Henriksson R. FACT an open label randomized phase III study comparing fulvestrant and anastrozole in combination compared with anastrozole alone as first line therapy for receptor positive postmenopausal breast cancer patients. *Journal of Clinical Oncology* 20: 1919-1925, 2012.
293. Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grander D, Sangfeldt O. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favourable prognosis in primary breast cancer. *Breast Cancer Research* 12:R105, 2010.
294. Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Ilorca F, Pestalozzi B, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. *The Breast* 21: 20-6, 2012.
295. Millstein JD, Volfson JR, Lamb S, Friend H, Dai EE, Schadt, Bergh J. Permutation-based yet computationally parsimonious FDR point and confidence interval estimators. In *JSM Proceedings, ENAR*. Alexandria, VA: American Statistica Association 4184-4197, 2010.
296. Early Breast Cancer Trialists' Collaborative Group (EBCTCG\*). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. (\*Jonas Bergh member of Steering Committee.) *The Lancet* 378; 771-84, 2011.
297. Coleman MP, Forman D, Bryant J, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahn CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, and the ICBP Mouldle 1 Working Group including Bergh J and many more. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarkin Partnership): an analysis of population-based cancer registry data. *The Lancet* 377:127-138, 2011.
298. Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO, Jakobsen E, Møller S, Lindman H, Blomqvist C. Dose tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase III adjuvant Trial SBG 2000-1. *Acta Oncologica* 50:329-337, 2011.
299. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman M, Bergh J, Nitz UA, Gianni AM, Bassar RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem cell support as adjuvant therapy in

- breast cancer: Overview of 15 randomized trials. *Journal of Clinical Oncology* 29: 3214-23, 2011.
300. Early Breast Cancer Trialists' Collaborative Group (EBCTCG\*) Effect of Radiotherapy after Breast-conserving Surgery on 10 year Recurrence and 15 year Breast Cancer Mortality in Women with Early Breast Cancer: Analysis of Individual Patient Data on 10,801 Women in 17 Randomised Trials. (\*Jonas Bergh member of Steering Committee). *The Lancet* 378:1707-16, 2011.
  301. Early Breast Cancer Trialists' Collaborative Group (EBCTCG\*). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of medium and long-term outcomes in 100,000 randomised women. (\*Jonas Bergh member of Steering Committee & writing committee). *The Lancet* 379:432-444, 2012.
  302. Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, Teo AS, Woo XY, Zhang Z, Zhao H, Ukil L, Chen JP, Zhu F, So JB, Salto-Tellez M, Poh WT, Zawack KF, Nagarajan N, Gao S, Li G, Kumar V, Lim HP, Sia YY, Chan CS, Leong ST, Neo SC, Choi PS, Throeau H, Tan PB, Shahab A, Ruan X, Bergh J, Hall P, Cacheux-Rataboul V, Wei CL, Yeoh KG, Sung WK, Bourque G, Liu ET, Ruan Y. Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. *Genome Research* 5: 665-75, 2011.
  303. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS, Desai KV, Bergh J, Hall P, Putti TC, Ong WL, Shahab A, Cacheux-Rataboul V, Karuturi RK, Sung WK, Ruan X, Bourque G, Ruan Y, Liu ET. Transcriptional Consequences of Genomic Structural Aberrations in Breast Cancer. *Genome Research* 5: 676-87, 2011.
  304. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM. An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer. *Cancer Research* 71: 6728-6737, 2011.
  305. Rosin G, Hannelius U, Lindström L, Hall P, Bergh J, Hartman J, Kere J. The Dyslexia Candidate Gene *DYX1C1* is a Potential Marker of Poor Survival in Breast Cancer. *BMC Cancer* 12:79, 2012.
  306. Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz T, Hellström M, Svensson H, Åström G, Brandberg Y, Carstensen J, Fernö M, Bergh J for the TEX Study Group Departments. Individually Tailored Treatment with Epirubicin and Paclitaxel With or Without Capecitabine as First-line Chemotherapy in Metastatic Breast Cancer. A Randomised Multicentre Trial. *Breast Cancer Research and Treatment* 131:939-947, 2012.
  307. Wennmalm K, Bergh J. A simple method for assigning genomic grade to individual breast tumours. *BMC Cancer* 11:306, 2011.
  308. Jonsson, B & Bergh, J. Hurdles in anticancer drug development from a regulatory perspective. *Nature Review Clinical Oncology*. *Nature Reviews Clinical Oncology* 9:236-243, 2012.
  309. Steven A. Eschrich, William J.Fulp, M.S., Yudi Pawitan, John Foekens, MD, Marcel Smid, Michelle Echevarria, M.S., Vidya Kamath, Ph.D., Ji-Hyun Lee, Eleanor E. Harris, Jonas

Bergh, and Javier F. Torres-Roca, Validation of a Radiosensitivity in Molecular Signature in Breast Cancer. *Clinical Cancer Research* 18:5134-43, 2012.

310. Prat A, Parker JS, Fan C, Cheang MCU, Miller LD, Bergh J, Chia SKL, Bernard PS, Nielsen TO, Ellis MJ, Carey, Perou C. Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. *Annals of Oncology* 23:2866-73, 2012.
311. Kaufman M, von Minckwitz G, Bergh J, Conte P-F, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D, Senn H-J, Viale G, Loibl S. 1<sup>st</sup> International Consensus Guidelines for Advanced Breast Cancer (ABC1). *Breast* 21:242-252, 2012.
312. Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz T, Fernö M, Bergh J, Hatschek T. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. *Breast Cancer Research and Treatment* 139:751-758, 2013.
313. Foukakis T, Åström G, Lindström L, Hatschek T, Bergh J. When to order a biopsy to characterize a metastatic relapse in breast cancer. *Annals of Oncology* 23 (supplement 10) x349-53, 2012.
314. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagni O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssmi N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van't Veer L, Viale G, Krop I, Winer E. First International Consensus Guidelines for Advanced Breast Cancer (ABC1). *Breast* 21:242-252, 2012.
315. Lindström L and Karlsson E, Wilking U, Johansson U, Lidbrink E, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers are unstable throughout tumor progression. *Journal of Clinical Oncology* 30:2601-2608, 2012.
316. Pritchard KI, Bergh J, Burstein HJ. Update of the Oxford Overview: New Insights and Perspectives in the Era of Personalized Medicine. *ASCO Educational Book 2012* pp 71-79 (online at asco.org, copyright 2012 Alexandria, VA)
317. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD. Interactions between Immunity, Proliferation and Molecular Subtype in Breast Cancer Prognosis. *Genome Biology* 14: R34, 2013.
318. Tobin N, Bergh J. Analysis of Cyclin D1 in Breast Cancer: A Call to Arms. *Current Breast Cancer Reports* 4;3:171-173, 2012.
319. Frings O, Augsten M, Tobin N, Carlson J, Paulsson J, Pena C, Olsson E, Veerla S, Bergh J, Östman A, Sonnhammer E. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. *The American Journal of Pathology* 182:2037-2047, 2013.
320. Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Wärnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB,

Lawrence G, C McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP and The ICBP Module 1 Working Group. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *British Journal of Cancer* 108:1195-1208, 2013.

321. Tobin N, Lindström L, Carlson JW, Bjöhle J, Bergh J and Wennmalm K: Multi-level gene expression signatures, but not binary, outperform Ki67 for short and long term prognostication in two population derived breast cancer materials. *Molecular Oncology* 8:741-752, 2014.
322. Milosevic J and Klinge J, Borg A-L, Foukakis T, Bergh J and Tobin NP. Clinical instability of breast cancer markers is reflected in long term *in vitro* estrogen deprivation studies. *BMC Cancer* 13:473, 2013.
323. Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, Foukakis T. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. *Breast Cancer Research and Treatment* 147: 407-414, 2014.
324. Kessler L, Falato C, Margolin S, Bergh J, Foukakis T. A retrospective safety and efficacy analysis of patients with eribulin for metastatic breast cancer in Stockholm, Sweden. *Acta Oncologica* 54:522-529, 2015.
325. Klevebring D, Rosin G, Ma R, Lindberg J, Czene K, Kere J, Fredriksson I, Bergh J and Hartman J. Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states *in vivo*. *Breast Cancer Research* 16:R72, 2014.
326. Bergh J, Hall P, Östman A, Toftgård R. Breast cancer biology and the future of tailored therapies. *Journal of Internal Medicine* 274:102-104, 2013.
327. Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjöblom T and Bonnefoi H. Validation of a yeast functional assay for p53 mutations using clonal sequencing. *The Journal of Pathology* 231:441-448, 2013.
328. Goldhirsch A, Winer E.P, Coates A.S, Gelber R.D, Piccart-Gebhart M, Thürlimann B, Senn H.-J and Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology* 24: 2206-2223, 2013.
329. Cortazar P, Zhang L, Untch M, Mehta K, Constantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain S.M, Prowell T, Loibl S, Wickerham L, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas E, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara M, Fasching P, Zujewski J-A, Slaets L, Tang S, Gerber B, Geyer C, Pazdur R, Ditsch N, Rastogi R, Eiermann W, and von Minckwitz G. Pathological Complete Response in Breast Cancer: CTNeoBC Pooled-Analysis. *The Lancet* 384(9938):164-172, 2014.
330. Linderholm B.K, Lidbrink E, Tallroth E, Einbeigi Z, Svensson H, von Wachenfeldt A, Norberg B, Carlsson L, Olsson M.E, Bergh J, Wilking N and Hatschek T. Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel. *The Breast* 22:1142-1147, 2013.

331. Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J. Breast cancer during follow-up and progression – A population based cohort on new cancers and changed biology. *European Journal of Cancer* 50:2916-24, 2014.
332. Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F. Clonal alteration of breast cancer receptors between primary Ductal Carcinoma In Situ (DCIS) and corresponding local events. *European Journal of Cancer* 50:517-524, 2014.
333. Hong J, Tobin NP, Rundqvist H, Li T, Lavergne M, Garcia-Ibáñez Y, Qin H, Paulsson J, Zeitelhofer M, Adzemovic MZ, Nilsson I, Roswall P, Hartman J, Johnson RS, Östman A, Bergh J, Poljakovic M, Genové G. Role of tumor pericytes in the recruitment of myeloid-derived suppressor cells. *Journal of the National Cancer Institute* 107:10, 2015.
334. Kaufmann M, von Minckwitz G, Bergh J, Conte P-F, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D, Senn H-J, Viale G, Loibl S. Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. *Archives of Gynecology and Obstetrics* 288:1203-1212, 2013.
335. Stålhammar G, Rosin G, Fredriksson I, Bergh J, Hartman J. Low concordance of biomarkers in histopathological and cytological material from breast cancer. *Histopathology* 64(7):971-80, 2014.
336. Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte p, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Höjgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinskik C, Zur Hausen H, Johnston PG. A Catalyst for Change: The European Cancer Patient's Bill of Rights. *Oncologist* 19:217-224, 2014.
337. Foukakis T, Lövrot J, Sandqvist P, Xie H, Lindström L, Giorgetti C, Jacobsson H, Hedayati E, Bergh J. Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. *Molecular Oncology* 9:1384-91, 2015.
338. Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA, EORTC 10994/BIG 1-00 Study Investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. *Annals of Oncology* 25:1128-1136, 2014.
339. EBCTCG (Early Breast Cancer Trialists' Collaborative Group)\*. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. (\*Jonas Bergh member of Steering Committee & co-Chairman for EBCTCG). *The Lancet* 383:2127-2135, 2014.
340. Ma R, Fredriksson I, Govindasamy-Muralidharan K, Winn G, Darai-Ramqvist E, Bergh J and Hartman J. Superficial scrapings from breast tumors is a source for biobanking and research purposes. *Laboratory Investigation* 94:796-805, 2014.

341. Rosin G, de Boniface J, Govindasamy-Muralidharan K, Frisell J, Bergh J and Hartman J. Oestrogen receptor  $\beta$  and  $\beta$ cx have divergent roles in breast cancer survival and lymph node metastasis. *British Journal of Cancer* 111: 918-926, 2014.
342. Boix-Perales H, Borregaard J, Bech Jensen K, Ersböll J, Galluzzo S, Guiliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens J, Pignatti F. The European Medicines Agency review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. *Oncologist* 19:766-773, 2014.
343. Tobin N, Harrell J C, Lövrot J, Egyhazi Brage S, Frostvik-Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou C, Bergh J, Hatschek T, Lindström L; TEX Trialists Group. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. *Annals of Oncology* 26: 81-88, 2014.
344. Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C. miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. *Molecular Oncology* 8:1690-1702, 2014.
345. Foukakis T, Lövrot J, Bergh J. Thyroid hormone inactivation in gastrointestinal stromal tumors (correspondence). *The New England Journal of Medicine* 371: 84-85, 2014.
346. von Stedingk H, Xie H, Hatschek T, Foukakis T, Rydén A, Bergh J, Rydberg P. Validation of a novel procedure for quantification of the formation of phosphoramidate mustard by individuals treated with cyclophosphamide. *Cancer Chemotherapy and Pharmacology* 74: 549-558, 2014.
347. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Paganì O, Partridge A, Penault-LLorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, vant't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2<sup>nd</sup> international consensus guidelines for advanced breast cancer (ABC2). *The Breast* 23: 489-502, 2014. AND: *Annals of Oncology* 25:1871-1888, 2014.
348. Browall M, Brandberg Y, Nasic S, Rydberg P, Bergh J, Rydén A, Xie H, Wengström Y. A prospective exploration of symptom burden clusters for women with breast cancer during chemotherapy treatment. *Support Care Cancer* 25:1423-1429, 2017.
349. Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Bruins Slot K, Damkier P, Hofland K, Borregaard J, Ersböll J, Salmonsson T, Pieters R, Sylvester R, Mickish G, Bergh J, Pignatti F, EMEA. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: Summary of the scientific assessment of the Committee for Medical Products for Human Use (CHMP). *Oncologist* 20:196-201, 2015.
350. Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindström L, Törnberg S, Hall P, Czene K. Breast cancer genetic risk profile is differentially associated with interval and screen-detected

breast cancers. *Annals of Oncology* 26:517-522, 2015.

351. Cunha S, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller B K, Pearsall R S, Mulivor A W, Kumar R, Larsson C, Bergh J, Pietras K. Endothelial AXL1 is a therapeutic target to block metastatic dissemination of breast cancer. *Cancer Research* 75:2445-2456, 2015.
352. Johansson HJ, Sanchez BC, Forshed J, Stål O, Fohlin H, Lewensohn R, Hall P, Bergh J, Lehtiö J, Linderholm BK. Proteomics profiling identity CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. *Clinical Proteomics* 12:8, 2015.
353. Tobin NP, Foukakis T, De Petris L, Bergh J. The importance of molecular markers for diagnosis and selection of targeted treatments with cancer patients. *Journal of Internal Medicine* 278:545-570, 2015.
354. Ekholm M, Grabau D, Bendahl P-O, Bergh J, Elmberger G, Olsson H, Russo L, Viale G, Fernö M. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. *Acta Oncologica* 54:1040-1048, 2015.
355. Gnant M, Pfeiler G, Dubsy PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevela P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSC-18): a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet* 386:433-443, 2015.
356. Karthik GM, Ma R, Lövrot J, Kis LL, Lindh C, Blomquist L, Fredriksson I, Bergh J, Hartman J. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. *Cancer Letters* 367:76-78, 2015.
357. EBCTCG (Early Breast Cancer Trialists' Collaborative Group)\*. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. (\*Jonas Bergh member of Steering Committee & co-Chairman for EBCTCG & writing committee). *The Lancet* 386:1353-1361, 2015.
358. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology* 26:1533-1546, 2015.
359. Kimbung S, Kovács A, Danielsson A, Bendahl PO, Lövgren K, Stolt MF, Tobin NP, Lindström L, Bergh J, Einbeigi Z, Fernö M, Hatschek T, Hedenfalk I. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. *Oncotarget* 6:33306-33318, 2015.
360. Falato C, Tobin NP, Lorent J, Lindström LS, Bergh J, Foukakis T. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. *Molecular Oncology* 10:517-525, 2016.

361. Tobin N, Wennmalm K, Lindström L, Foukakis T, He L, Genové G, Östman A, Landberg G, Betsholtz C, Bergh J. An endothelial gene signature score predicts poor outcome in patients with endocrine treated, low genomic grade breast tumors. *Clinical Cancer Research* 22:2417-2426, 2016.
362. Bergh J, Pritchard KI, Cameron D. Sisyphean efforts: Establishing the correct risk-benefit balance for adjuvant therapies. *Journal of Clinical Oncology* 34:895-897, 2016.
363. Papakonstantinou A, Foukakis T, Rodriguez-Wallberg K, Bergh, J. Oncology Grand Round: Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? *Journal of Clinical Oncology* 34:1573-1579, 2016.
364. Hadji P, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, Costa L, Body J, Markipoulos C, Santini D, Dien I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert U, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Annals of Oncology* 27:379-390, 2016.
365. Stålhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Mölholm I, Kis L, Rosin G, Rantalainen M, Pedersen L, Bergh J, Grunkin M, Hartman J. Digital image analysis outperforms manual biomarker assessment in breast cancer. *Modern Pathology* 29:318-329, 2016.
366. Wallerius M, Wallmann T, Bartish M, Östling J, Mezheyeuski A, Tobin N, Nygren E, Pangigadde P, Pellegrini P, Squadrito ML, Pontén F, Hartman J, Bergh J, De Milito A, De Palma M, Östman A, Andersson J, Rolny C. Guidance molecule SEMA3A restricts tumor growth by differentially regulating proliferation of tumor-associated macrophages. *Cancer Research* 76:3166-78, 2016.
367. Taylor C, Correa C, Duane F, Aznar M, Anderson S, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard K, Swain S, Wang Z, Whelan T, Peto R, McGale P for the EBCTCG. Estimating the risks of breast cancer radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomised trials. *Journal of Clinical Oncology* 35:1641-1649, 2017.
368. Brand J, Hall P, Bergh J, Giesecke J, Clements M, Johansson A, Colzani E, Czene K. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. *Journal of Infection* 72:650-658, 2016.
369. Foukakis T, Falato C, Bergh J. A 21-gene expression assay in breast cancer. *The New England Journal of Medicine* (correspondence) 374:1385-1387, 2016.
370. Foukakis T, von Minckwitz G, Bengtsson N-O, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer C, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J on behalf of the Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG) and the Austrian Breast & Colorectal Cancer Study Group (ABCSCG). Effect of tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. *The Journal of the American Medical Association* 316:1888-1896, 2016.



371. Sjöberg E, Augsten M, Bergh J, Jirström K, Östman A. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. *British Journal of Cancer* 114:117-1124, 2016.
372. Li J, Ivansson E, Klevebring D, Tobin N, Lindström L, Holm J, Prochazka G, Cristando C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Czene K. Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes. *Clinical Cancer Research* 23:2584-2592, 2017.
373. Brand J, Hedayati E, Humphreys K, Ludvigsson J, Johansson A, Bergh J, Hall P, Czene K. Chemotherapy, genetic susceptibility and risk of venous thromboembolism in breast cancer patients. *Clinical Cancer Research* 22:5249-5255, 2016.
374. Saracco A, Szabó BK, Tánzos E, Bergh J, Hatschek T. Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy. *Acta Radiologica* 58:394-402, 2017.
375. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group. *Annals of Oncology* 27:13778-1381, 2016.
376. Fredholm H, Magnusson K, Lindström L, Garmo H, Fält SE, Lindman H, Bergh J, Holmberg L, Pontén F, Frisell J, Fredriksson I. Long-term outcome in young women with breast cancer: a population-based study. *Breast Cancer Research and Treatment* 160:131-143, 2016.
377. Prakash V, Carson BB, Feenstra JM, Dass RA, Sekyrova P, Hoshino A, Petersen J, Guo Y, Parks MM, Kurylo CM, Batchelder JE, Haller K, Hashimoto A, Rundqvist H, Condeelis JS, Allis CD, Drygin D, Nieto MA, Andäng M, Percipalle P, Bergh J, Adameyko I, Farrants AÖ, Hartman J, Lyden D, Pietras K, Blanchard SC, Vincent CT. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. *Nature Communications* 10:2110, 2019.
378. Delcoigne B, Hagenbuch N, Schelin ME, Salim A, Lindström L, Bergh J, Czene K, Reilly M. Feasibility of reusing time-matched controls in an overlapping cohort. *Statistical Methods in Medical Research* Sep 21, pii: 0962280216669744, 2016.
379. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernaut-Llorca F, Piccart M, Pierga J, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3<sup>rd</sup> ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3). *Annals of Oncology* 28:16-33, 2017.
380. Brand J, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K, Ludvigsson J, Czene K. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. *Cancer* 123:468-475, 2017.

381. Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, Celebioglu F, Fredriksson I, Czene K, Frisell J, Hartman J, Bergh J, Grönberg H. Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. *Scientific Reports* 6:38037, 2016.
382. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Taberner J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016. *ESMO Open* 1(5):e000097. Review, 2016.
383. Pavlidis N, Alba E, Berardi R, Bergh J, El Saghir N, Jassem J, Kosty M, Lopez RI, Lotz JP, Österlund P, Purkalne G, Dittrich C. The ESMO/ASCO global curriculum and the evolution of medical oncology training in Europe. *ESMO Open* 1(1):e000004, 2016.
384. Cardoso F, Harbeck N, Barrois CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CS, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA. Research needs in breast cancer. *Annals of Oncology* 28:208-217, 2017.
385. Paulsson J, Rydén L, Strell C, Frings O, Tobin NP, Fornander T, Bergh J, Landberg G, Stål O, Östman A. High expression of stromal PDGFR $\beta$  is associated with reduced benefit of tamoxifen in breast cancer. *Journal of Pathology: Clinical Research* 3:38-43, 2017
386. Dittrich C, Kosty MP, Jezdic S, Pyle S, Berardi R, Bergh J, El-Saghir NS, Lotz JP, Österlund P, Pavlidis N, Purkalne G. Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology. *Journal of Clinical Oncology* 35:254-255, 2017.
387. Rudewicz J, Soueidan H, Uricaru R, Bonnefoi H, Iggo R, Bergh J, Nikolski M. MICADo – Looking for mutations in targeted PacBio cancer data: an alignment-free method. *Frontiers in Genetics* 7: 214, 2016.
388. Foukakis T, Bergh J. Kemoterapi och målstyrda läkemedel kan förstärka varandra. *Läkartidningen* 114:EEIS, 2017.
389. Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen T, Arnes J, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson I, Birkeland E, Aas T, Tobin N, Jonassen I, Bergh J, Foulkes W, Akslen L. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. *Scientific Reports* 7:1089, 2017.
390. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF for the EBCTCG. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *The New England Journal of Medicine* 377:1836-

46, 2017.

391. Matikas A, Foukakis T, Bergh J. Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. *Critical Reviews in Oncology/Hematology* 114:91-191, 2017.
392. Strell C, Paulsson J, Jin SB, Tobin NP, Mezheyeuski A, Roswall P, Mutgan C, Mitsios N, Johansson H, Wickberg SM, Svedlund J, Nilsson M, Hall P, Mulder J, Radisky DC, Pietras K, Bergh J, Lendahl U, Wärnberg F, Östman A. Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. *Journal of the National Cancer Institute* 111:983-995, 2019.
393. Matikas A, Foukakis T, Bergh J. Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts, *Acta Oncologica* 56:1143-1151, 2017.
394. EBCTCG (Early Breast Cancer Trialists' Collaborative Group)\*. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. (\*Jonas Bergh member of Steering Committee & co-Chairman for EBCTCG & writing committee). *The Lancet Oncology* 19:27-39, 2018.
395. Fredholm H, Magnusson K, Lindström L, Tobin, N, Lindman H, Bergh J, Holmberg L, Pontén F, Frisell J, Fredriksson I. Breast cancer in young women and prognosis – how important are proliferation markers? *European Journal of Cancer* 84:278-289, 2017.
396. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Annals of Oncology* 28:1700-1712, 2017.
397. Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Patricia M, Huang L, Meinhardt G, Zhang J, Schwartzberg LS. RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer. *Clinical Breast Cancer* 17:585-594, 2017.
398. Tzogani K, Camarero Jiménez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency review of carfilzomib for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. *Oncologist* 22:1339-1346, 2017.
399. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty\*. Societal challenges of precision medicine: Bringing order to chaos. (\*J Bergh member). *European Journal of Cancer* 84:25-

400. Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albrecht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Taberero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P. The European cancer patient's bill of rights, update and implementation 2016. *ESMO Open* 1(6):e000123, 2017.
401. Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T. PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients. *Clinical Cancer Research* 23:7225-7231, 2017.
402. Lundberg A, Lindström LS, Harrell JC, Falato C, Carlson JW, Wright PK, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts. *Clinical Cancer Research* 23:7512-7520, 2017.
403. Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. *International Journal of Cancer* 142:618-628, 2018.
404. Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. *Breast Cancer Research and Treatment* 167:761-769, 2018.
405. Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of panobinostat (Farydak) for the treatment of adult patients with relapsed and/or refractory multiple myeloma. *The Oncologist* 23: 631-636, 2018.
406. Matikas A, Margolin S, Hellström M, Johansson H, Bengtsson NO, Karlsson L, Edlund P, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmstrom P, Villman K, Foukakis T, Bergh J. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. *Breast Cancer Research and Treatment* 168:349-355, 2018.
407. Karthik GM, Rantalainen M, Stålhammar G, Lövrot J, Ullah I, Alkodsai A, Ma R, Wedlund L, Lindberg J, Frisell J, Bergh J, Hartman J. Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. *BMC Cancer*, 17:802, 2017.
408. Palazon A, Tyrakis PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, Hatschek T, Lövrot J, Foukakis T, Goldrath AW, Bergh J, Johnson RS. An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression.

Cancer Cell 32:669-683, 2017.

409. Stålhammar G, Robertson S, Wedlund L, Lippert M, Rantalainen M, Bergh J, Hartman J. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. *Histopathology* 72:974-989, 2018.
410. Mijwel S, Backman M, Bolam KA, Olofsson E, Norrbom J, Bergh J, Sundberg CJ, Wengström Y, Rundqvist H. Highly favourable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. *Breast Cancer Research and Treatment* 169:93-103, 2018.
411. Eriksson L, Bergh J, Humphreys K, Wärnberg F, Törnberg S, Czene K. Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study. *International Journal of Cancer* 143:1093-1104, 2018.
412. Robertson S, Stålhammar G, Darai-Ramqvist E, Rantalainen M, Tobin NP, Bergh J, Hartman J. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. *Journal of Clinical Pathology* 71:787-794, 2018.
413. Lindman H, Andersson M, Ahlgren J, Balslev E, Sverrisdottir A, Holmberg SB, Bengtsson NO, Jacobsen EH, Jensen AB, Hansen J, Tuxen MK, Malmberg L, Villman K, Anderson H, Ejlersen B, Bergh J, Blomqvist C; Swedish Breast Cancer Group (SweBCG), the Danish Breast Cancer Group (DBCG) and the Scandinavian Breast Cancer Group (SBG). A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). *European Journal of Cancer* 94:79-86, 2018.
414. Aalders KC, Touati N, Tryfonidis K, Annonay M, Litiere S, Bergh J, Bodmer A, Cameron DA, Bonnefoi HR; EORTC 10994/BIG 1-00 Study Investigators. Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. *Breast Cancer Research and Treatment* 169:497-505, 2018.
415. Kjällquist U, Erlandsson R, Tobin NP, Alkodsı A, Ullah I, Stålhammar G, Karlsson E, Hatschek T, Hartman J, Linnarsson S, Bergh J. Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). *BMC Cancer* 18:174, 2018.
416. Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T. Immune gene expression and response to chemotherapy in advanced breast cancer. *British Journal of Cancer* 118:480-488, 2018.
417. Ullah I, Karthik GM, Alkodsı A, Kjällquist U, Stålhammar G, Lövrot J, Martinez NF, Lagergren J, Hautaniemi S, Hartman J, Bergh J. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. *The Journal of Clinical Investigation* 128:1355-1370, 2018.
418. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene* 37:4639-4661, 2018.

419. Mutvei AP, Landor SK, Fox R, Braune EB, Tsoi YL, Phoon YP, Sahlgren C, Hartman J, Bergh J, Jin S, Lendahl U. Notch signaling promotes a HIF2 $\alpha$ -driven hypoxic response in multiple tumor cell types. *Oncogene* 37:6083-6095, 2018.
420. Wallmann T, Zhang XM, Wallerius M, Bolin S, Joly AL, Sobocki C, Leiss L, Jiang Y, Bergh J, Holland EC, Enger PØ, Andersson J, Swartling FJ, Miletic H, Uhrbom L, Harris RA, Rolny C. Microglia induce PDGFRB expression in glioma cells to enhance their migratory capacity. *iScience* 9:71-83, 2018.
421. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Annals of Oncology* 29:1634-1657, 2018.
422. Sim S, Lövrot J, Lindh JD, Bergh J, Xie H. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. *Pharmacogenomics* 19:1027-1037, 2018.
423. Sjöström M, Staaf J, Edén P, Wärnberg F, Bergh J, Malmström P, Fernö M, Niméus E, Fredriksson I. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. *Breast Cancer Research* 20:64, 2018.
424. Matikas A, Lövrot J, Ramberg A, Eriksson M, Lindsten T, Lekberg T, Hedenfalk I, Loman N, Bergh J, Hatschek T, Erlandsson A, Foukakis T. Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. *Oncoimmunology* Jul 26;7(9):e1466017, 2018.
425. Falato C, Taylor SK, Szulkin R, Nordblom A, Eriksson L, Sofiadis A, Fredriksson I, Hartman J, Bergh J, Foukakis T. Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry. *Breast Cancer Research and Treatment* 172:703-712, 2018.
426. Sim S, Bergh J, Hellström M, Hatschek T, Xie H. Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. *Pharmacogenomics* 19:1259-1268, 2018
427. Blumenthal GM, Bunn PA Jr, Chافت JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruyscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. *Journal of Thoracic Oncology* 13:1818-1831, 2018.
428. Svedlund J, Strell C, Qian X, Zilkens KJC, Tobin NP, Bergh J, Sieuwerts AM, Nilsson M. Generation of in situ sequencing based OncoMaps to spatially resolve gene expression

profiles of diagnostic and prognostic markers in breast cancer. *EBioMedicine* Sep 13. pii: S2352-3964(19)30607-3, 2019.

429. Matikas A, Foukakis T, Bergh J. Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology. *Journal of Internal Medicine* 285:395-397, 2019.
430. Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson G, Ringnér M, Bergh J, Björklund Å, Pietras K. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. *Nature Communications* 9:5150, 2018.
431. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Annals of Oncology* 30:1181, 2019.
432. Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Becette V, Kerdraon O, Bibeau F, Ghnassia J-P, Picquetot J-M, Thomas J, Tille J-C, Slaets L, Bodmer A, Bergh J, Cameron D on behalf of the EORTC 10994/BIG 1-00 study investigators. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. *British Journal of Cancer* 120:913-921, 2019.
433. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)\*. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. (\*Jonas Bergh member of Steering Committee & co-Chairman for EBCTCG & writing committee). *The Lancet* 393:1440-1452, 2019.
434. Sandri BJ, Masvidal L, Murie C, Bartish M, Avdulov S, Higgins L, Markowski T, Peterson M, Bergh J, Yang P, Rolny C, Limper AH, Griffin TJ, Bitterman PB, Wendt CH, Larsson O. Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. *American Journal of Respiratory and Critical Care Medicine* 200:348-358, 2019.
435. Wendt CH, Sandri BJ, Masvidal L, Murie C, Bartish M, Avdulov S, Higgins L, Markowski T, Peterson M, Bergh J, Yang P, Rolny C, Limper AH, Griffin TJ, Bitterman PB, Larsson O. Chronic Obstructive Pulmonary Disease Phenotype Dictates Cancer-Promoting Stromal Gene Expression Programs. *Annals of the American Thoracic Society* Dec;15(Supplement\_4): S290-S291, 2018.
436. Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. *Breast Cancer Research* 21:36, 2019.
437. Lundberg A, Lindström LS, Li J, Harrell JC, Darai-Ramqvist E, Sifakis EG, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. *Breast Cancer Research* 21:34, 2019.

438. Poikonen-Saksela P, Lindman H, Sverrisdottir A, Edlund P, Villman K, Tennvall Nittby L, Cold S, Bechmann T, Stenbygaard L, Ejlersen B, Andersson M, Blomqvist C, Bergh J, Ahlgren J. Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1. *Acta Oncologica* 59:825-832, 2020.
439. Tsagozis P, Augsten M, Zhang Y, Li T, Hesla A, Bergh J, Haglund F, Tobin NP, Ehnman M. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. *Cancer Immunology, Immunotherapy* 68:927-936, 2019.
440. Matikas A, Foukakis T, Swain S, Bergh J. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? *Annals of Oncology* 30:1044-1050, 2019.
441. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, Wengström Y. High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship. *Journal of Cancer Survivorship* 13:244-256, 2019
442. Brandberg Y, Johansson H, Hellström M, Gnant M, Möbus V, Greil R, Foukakis T, Bergh J; Swedish Breast Cancer Group, the Austrian Breast, Colorectal Cancer Study Group, the German Breast Cancer Group. Long-term (up to 16 months) health related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. *Breast Cancer Research and Treatment* 181:87-96, 2020.
443. Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, Steger G, Greil R, Untch M, Moebus V, Loibl S, Foukakis T, Bergh J\*, Matikas A\*. \*These authors contributed equally. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. *Acta Oncologica* 59:75-81, 2020.
444. Chrétien S, Zerdes I, Bergh J, Matikas A, Foukakis T. Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. *Cancers (Basel)* 11(5), 2019.
445. Matikas A, Zerdes I, Lövrot J, Richard F, Sotiriou C, Bergh J, Valachis A, Foukakis T. Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. *Clinical Cancer Research* 25:5717-5726, 2019.
446. Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson N-O, Steger G, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J on behalf of the SweBCG, ABCSG and GBG. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. *Annals of Oncology* 30:109-114, 2019.
447. Hedayati E, Papakonstantinou A, Gernaat SAM, Altena R, Brand JS, Alfredsson J, Bhoo-Pathy N, Herrmann J, Linde C, Dahlstrom U, Bergh J, Hubbert L. Outcome and Presentation of Heart Failure in Breast Cancer Patients; Findings from a Swedish register-based study. *The European Heart Journal – Quality of Care and Clinical Outcomes* 6:147-155, 2019.
448. Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P, Czene K. Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer. *JNCI Cancer Spectrum*



2(4):pky071, 2019.

449. Schmid P, Cortes J, Puzstai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J. Pembrolizumab for Early Triple-Negative Breast Cancer. *The New England Journal of Medicine* 382:810-821, 2020.
450. Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. *ESMO Open* 4(5):e000570, 2019.
451. Zerdes I, Wallerius M, Sifakis EG, Wallmann T, Betts S, Bartish M, Tsesmetzis N, Tobin NP, Coucoravas C, Bergh J, Rassidakis GZ, Rolny C, Foukakis T. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. *Cancers (Basel)* 11(10), 2019.
452. Ali S, Kjekken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. *Oncologist* 25:e321-e327, 2020.
453. Zerdes I, Sifakis EG, Matikas A, Chrétien S, Tobin NP, Hartman J, Rassidakis GZ, Bergh J, Foukakis T. Programmed Death Ligand-1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. *Molecular Oncology* 14: 951-963, 2020.
454. Bartish M, Tong D, Pan Y, Wallerius M, Liu H, Ristau J, de Souza Ferreira S, Wallmann T, van Hoef V, Masvidal L, Kerzel T, Joly AL, Goncalves C, Preston SEJ, Ebrahimian T, Seitz C, Bergh J, Pietras K, Lehoux S, Naldini L, Andersson J, Squadrito ML, Del Rincón SV, Larsson O, Rolny C. MNK2 governs the macrophage anti-inflammatory phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, Oct 19:201920377, 2020.
455. Ali S, Camarero J, Hennik PV, Bolstad B, Sommerfelt Grønvold M, Syvertsen C, Oddvar Strøm B, Ökvist M, Josephson F, Keller-Stanislawski B, Zafiropoulos N, Pean E, Bergh J, da Rocha Dias S, Pignatti F. European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. *ESMO Open* 5(6):e000798, 2020.
456. Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpieri O, Bergh J, Karres D, Tzogani K, Gisselbrecht C, Pignatti F. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. *The Oncologist* Apr;25(4):e709-e715, 2020.
457. Neo SY, Yang Y, Julien R, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, Wagner AK, Andersson J, de Boniface J, Bergh J, Murray S, Alici E, Childs R, Johansson M, Westerberg LS, Haglund F, Hartman J, Lundqvist A. CD73 Immune Checkpoint Defines

Regulatory NK-cells within the Tumor Microenvironment. *The Journal of Clinical Investigation* 130:1185-1198, 2019.

458. Langebäck A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, Ramos A D, Berggren A, Cao Y, Hartman J, van Weerden W, Bergh J, Nordlund P and Lööf S. CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. *Scientific Reports* 9:19384, 2019.
459. Papakonstantinou A, Matikas A, Bengtsson NO, Malmström P, Hedayati E, Steger G, Untch M, Hübbert L, Johansson H, Hellström M, Gnant M, Loibl S, Greil R, Moebus V, Foukakis T, Bergh J. Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial. *Cancer* 126:1175-1182, 2019.
460. Burstein HJ, Curigliano G, Loibl S, Dubsy P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B; Members of the St. Gallen International Consensus Panel\* on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. (\*Jonas Bergh is one of the St Gallen panel members). *Annals of Oncology* 30:1541-1557, 2019.
461. Marklund A, Eloranta S, Wikander I, Kitlinski ML, Lood M, Nedstrand E, Thurin-Kjellberg A, Zhang P, Bergh J, Rodriguez-Wallberg KA. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. *Human Reproduction* 35:929-938, 2020.
462. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. *Nature Medicine* 26:665-671, 2020.
463. Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulas V, Matikas A. Chemotherapy use near the end-of-life in patients with metastatic breast cancer. *Breast Cancer Research and Treatment* 181:645-651, 2020.
464. Lundberg A, Lindström LS, Parker JS, Löverli E, Perou CM, Bergh J, Tobin NP. A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. *Oncogene* 39:5430-5440, 2020.
465. Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. *British Journal of Clinical Pharmacology* 26:1-10, 2020.
466. Edman Kessler L, Wiklander O, Hamberg E, Bergh J, Foukakis T, Matikas A. Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. *Acta Oncologica* 12:1-6, 2020.
467. Hedayati E, Papakonstantinou A, Månsson-Broberg A, Bergh J, Hübbert L, Altena R. Approaches to management of cardiovascular morbidity in adult cancer patients - cross-sectional survey among cardio-oncology experts. *Cardio-Oncology* 6:16, 2020.

468. Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, Sommerfelt Grønvold M, Sjøberg J, Botezatu M, Mulder J, Meulendijks D, Trullas Jimeno A, Zafiroopoulos N, Bergh J, Enzmann H, Pignatti F. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. *ESMO Open* 5(4):e000856, 2020.
469. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC5). *Annals of Oncology* Sep 23:S0923-7534(20)42460-3, 2020.
470. Matikas A, Zerdes I, Lövrot J, Sifakis E, Richard F, Sotiriou C, Rassidakis G, Bergh J, Valachis A, Foukakis T. PD-1 protein and gene expression as prognostic factors in early breast cancer. *ESMO Open*. Nov;5(6):e001032, 2020.
- .